Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety. [More]
Denator partners with Maastricht University to develop sample stabilization approaches for clinical applications

Denator partners with Maastricht University to develop sample stabilization approaches for clinical applications

Denator AB announced today that the company has entered into a 2-year collaboration with the Maastricht MultiModal Molecular Imaging Institute (M4I) of Maastricht University, the Netherlands. As part of the collaboration, Denator will work closely with the M4I Division of Imaging Mass Spectrometry, headed by university professor Ron Heeren, to jointly develop and evaluate innovative sample stabilization approaches for clinical applications. [More]
Limited anticancer role for preoperative statins in localised RCC setting

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests. [More]
IMDC prognostic model valid in second-line RCC therapy

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology. [More]
Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development. [More]
HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Patients with metastatic renal cell carcinoma reported a marked improvement in their health-related quality of life when given sunitinib on a 2 weeks on and 1 week off schedule compared with a 4 weeks on and 2 weeks off regimen, a Japanese study finds. [More]
Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. [More]
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
Lycera achieves milestone in Merck research collaboration

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. [More]
Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress. [More]
CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
Multimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCL

Multimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCL

Imaging techniques used to live in medical physics departments, where physicists worked on them, but now we're seeing biologists, cell biologists and developmental biologists looking at cellular processes and it's those advances that are really enabling imaging to move forward in a way that it hasn't previously been able to... [More]
DNA samples collected from tampons may help detect endometrial cancer

DNA samples collected from tampons may help detect endometrial cancer

Researchers at Mayo Clinic have shown that it is possible to detect endometrial cancer using tumor DNA picked up by ordinary tampons. The new approach specifically examines DNA samples from vaginal secretions for the presence of chemical "off" switches — known as methylation — that can disable genes that normally keep cancer in check. [More]
2015 Minds Matter event raises funds to support brain tumor research

2015 Minds Matter event raises funds to support brain tumor research

One day in 2009, Maria Nijim's father got behind the wheel of his car and realized he couldn't see out of one eye. An MRI showed a tumor and then surgery confirmed a devastating diagnosis – glioblastoma – the most aggressive type of brain tumor. [More]
TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA. [More]
TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015. [More]
Cancer-specific mortality lower in Asian Americans than non-Hispanic whites, shows study

Cancer-specific mortality lower in Asian Americans than non-Hispanic whites, shows study

Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been diagnosed with cancer, until now. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
Comprehensive medication assessment, monitoring plan needed to improve treatment for cancer patients

Comprehensive medication assessment, monitoring plan needed to improve treatment for cancer patients

Open the medicine cabinet of a senior and you're likely to find scores of pill bottles. Physicians are often unaware of all the medications a patient is taking, which can result in unnecessary additional prescriptions, non-prescription medications and potential drug-drug interactions that cause unexpected adverse effects. [More]
Advertisement
Advertisement